BEGIN:VCALENDAR
VERSION:2.0
PRODID:https://github.com/derhansen/sf_event_mgt
METHOD:PUBLISH
BEGIN:VEVENT
UID:756-199@badw.de
CLASS: PUBLIC
SUMMARY:From basic research to clinical application: Proteasome inhibitors 
 as drugs for blood cancer and autoimmune diseases
DESCRIPTION:The proteasome is the major intracellular protease. It cleaves 
 polypeptides in fragments to recycle their building blocks for de novo prot
 ein biosynthesis. This function is essential for controlling protein levels
 , removing damaged entities and ultimately ensuring cell survival. In addit
 ion, mammalian proteasome cleavage products are used for immune surveillanc
 e and protection against invaders like viruses. Since the 1990s inhibition 
 of the proteasome by small-molecules is being explored. These activities le
 d to the approval of three drugs that emerged to block busters and revoluti
 onized the treatment of multiple myeloma patients. In recent years, selecti
 ve inhibition of the immunoproteasome, a special proteasome version in immu
 ne cells, was shown to be therapeutically effective in autoimmune diseases 
 and chronic inflammations. Drug development efforts cumulated in phase II c
 linical trials, raising hopes for expanding the clinical application of pro
 teasome inhibitors in the future. This workshop will cover basic research o
 n proteasome inhibitor development and discuss clinical applications as wel
 l as future perspectives. The course addresses chemistry and biochemistry (
 PhD) students or postdocs a well as medical doctors.
LOCATION:Online-Veranstaltung
DTSTAMP:20251111T140042Z
DTSTART:20220221T080000Z
DTEND:20220221T140000Z
END:VEVENT
END:VCALENDAR